Research Paper Volume 13, Issue 17 pp 21232—21250

Figure 1. Expression of SNHG17 is enhanced in RCC and associated with poor prognosis. (A–B) qRT-PCR assay analysis of SNHG17 expression in human RCC tissues in patients from the Zhengzhou cohort (A) and TCGA-KIRC dataset (B). (C) qRT-PCR assay analysis of SNHG17 expression in RCC cell lines. (D) Predicted subcellular localization of SNHG17 using the "lnclocator" algorithm. (E) qRT-PCR assay analysis of the subcellular localization of SNHG17 in 786-O and ACHN cells. GAPDH and U6 served as a cytoplasmic and nuclear localization marker, respectively. (F) FISH assay analysis of the subcellular localization of SNHG17 in ACHN cells. (G–H) Kaplan-Meier survival curves showed that high expression of SNHG17 was related to dismal relapse-free (G) and overall survival (H) in patients with RCC from the Zhengzhou cohort. (I) High expression of SNHG17 was significantly associated with poor overall survival according to TCGA-KIRC dataset. RCC, renal cell carcinoma; TCGA, the cancer genome atlas; KIRC, kidney renal clear cell carcinoma; TT, tumor tissue; ANT, adjacent nontumor tissue. ^*P < 0.05; ^**P < 0.01; ^***P < 0.001.